User login
Breast cancer outcomes have improved significantly over the past 3 decades, with major gains in relapse-free survival and declines in mortality for all subtypes but particularly HER-2 positive breast cancer, a retrospective case-control study has found.
Researchers compared matched data from 7,178 women referred to the British Columbia Cancer Agency for breast cancer between 1986 and 1992 (C1) and mid-2004 and 2008 (C2) and found the risk of relapse halved in the second cohort, compared to the first, up to year 7 of follow-up, according to a paper published online Nov. 24 in the Journal of Clinical Oncology [doi:10.1200/JCO.2014.57.2461].
While there were similar patterns of disease relapse over time for both the estrogen receptor (ER)-negative and ER-positive patients between the two cohorts, the risk of relapse halved for ER-negative patients in the second cohort relative to the first, while the risk ratio for C2/C1 ranged from 0.26 to 0.56 in ER-positive patients.
“The greatest improvements in outcomes were achieved in the BC subtypes known to be more aggressive, namely the HER2-positive and ER-negative/HER2-negative patients,” wrote Dr. Rachel J.D. Cossetti and colleagues from the Vancouver (B.C.) Cancer Centre.The study was supported by coauthor Dr. Karen A. Gelmon, also of the Vancouver Cancer Centre.
Breast cancer outcomes have improved significantly over the past 3 decades, with major gains in relapse-free survival and declines in mortality for all subtypes but particularly HER-2 positive breast cancer, a retrospective case-control study has found.
Researchers compared matched data from 7,178 women referred to the British Columbia Cancer Agency for breast cancer between 1986 and 1992 (C1) and mid-2004 and 2008 (C2) and found the risk of relapse halved in the second cohort, compared to the first, up to year 7 of follow-up, according to a paper published online Nov. 24 in the Journal of Clinical Oncology [doi:10.1200/JCO.2014.57.2461].
While there were similar patterns of disease relapse over time for both the estrogen receptor (ER)-negative and ER-positive patients between the two cohorts, the risk of relapse halved for ER-negative patients in the second cohort relative to the first, while the risk ratio for C2/C1 ranged from 0.26 to 0.56 in ER-positive patients.
“The greatest improvements in outcomes were achieved in the BC subtypes known to be more aggressive, namely the HER2-positive and ER-negative/HER2-negative patients,” wrote Dr. Rachel J.D. Cossetti and colleagues from the Vancouver (B.C.) Cancer Centre.The study was supported by coauthor Dr. Karen A. Gelmon, also of the Vancouver Cancer Centre.
Breast cancer outcomes have improved significantly over the past 3 decades, with major gains in relapse-free survival and declines in mortality for all subtypes but particularly HER-2 positive breast cancer, a retrospective case-control study has found.
Researchers compared matched data from 7,178 women referred to the British Columbia Cancer Agency for breast cancer between 1986 and 1992 (C1) and mid-2004 and 2008 (C2) and found the risk of relapse halved in the second cohort, compared to the first, up to year 7 of follow-up, according to a paper published online Nov. 24 in the Journal of Clinical Oncology [doi:10.1200/JCO.2014.57.2461].
While there were similar patterns of disease relapse over time for both the estrogen receptor (ER)-negative and ER-positive patients between the two cohorts, the risk of relapse halved for ER-negative patients in the second cohort relative to the first, while the risk ratio for C2/C1 ranged from 0.26 to 0.56 in ER-positive patients.
“The greatest improvements in outcomes were achieved in the BC subtypes known to be more aggressive, namely the HER2-positive and ER-negative/HER2-negative patients,” wrote Dr. Rachel J.D. Cossetti and colleagues from the Vancouver (B.C.) Cancer Centre.The study was supported by coauthor Dr. Karen A. Gelmon, also of the Vancouver Cancer Centre.
FROM JOURNAL OF CLINICAL ONCOLOGY
Key clinical point: Breast cancer outcomes have improved significantly over the past 3 decades, with major gains in relapse-free survival and declines in mortality for all subtypes.
Major finding: The risk of relapse has halved for estrogen receptor–negative breast cancer since 1986.
Data source: Retrospective matched cohort study of 7178 women with breast cancer.
Disclosures: The study was supported by author Dr. Karen A. Gelmon.
